A hospital system’s mental health procurement runs through a clinical informatics officer, a compliance officer who answers to a hospital board, and a nursing leader with veto power over anything that touches patient workflow. A stablecoin card program’s procurement runs through a treasury lead, a VARA-licensed compliance officer in Dubai, and a risk desk pricing counterparty exposure. Neither buyer would recognize the other’s job title. But strip the vocabulary away, and the two buying processes are running on close to the same logic: a large committee, a long cycle, and a trust sequence that has to be built in a specific order before a sales conversation can even start.

That convergence is worth pausing on. Healthcare and fintech infrastructure sit in different regulatory universes, subject to different laws, different regulators and different failure modes. Yet the independently published go-to-market research on each category describes almost the same structural playbook, not because anyone copied the other, but because regulation seems to produce the same commercial shape wherever it shows up.

Both committees are the same order of magnitude, for the same reason

Enterprise SaaS sales cycles typically involve four to six stakeholders. Both regulated categories blow past that baseline by a similar multiple. Health system deals regularly involve twelve to twenty stakeholders, spanning the CMIO, the CIO, the CFO, the compliance officer, nursing leadership, IT security and procurement, each holding something close to a veto, with enterprise contracts running nine to twenty months [1]. Financial institution deals involve eight to twelve stakeholders, spanning product owners, technology leadership, compliance, legal, risk management and often a CISO, with cycles of six to eighteen months [2]. The exact headcounts differ, but both sit two to four times above a standard SaaS deal, and both take the better part of a year or more to close. Forrester’s research on enterprise buying has found that committee size correlates with cycle length across complex B2B sales generally, and healthcare and fintech infrastructure both land at the extreme end of that curve [1][2].

The reason is the same in both categories: regulatory exposure distributes decision rights across every function that could be blamed if the vendor fails. A hospital’s IT security team owns liability for a breach the same way a bank’s CISO does. A hospital’s compliance officer owns HIPAA exposure the same way a bank’s compliance team owns AML and licensing exposure. Neither institution lets one champion sign off on that much risk alone, which is a fact about regulated buying in general, not about healthcare or fintech specifically.

Regulatory trust has to come first, in both hierarchies

Fintech go-to-market guidance frames this explicitly as a hierarchy: regulatory trust first, then operational trust, domain trust, relationship trust, and only then brand trust, arguing that most companies over-invest in the last layer and skip the first [2]. Healthcare’s own playbook does not use the word hierarchy, but it describes the identical sequence: regulatory complexity is treated as the foundation the entire go-to-market motion is built on, not a compliance checkbox bolted on afterward, and clinical credibility has to be established before a buyer will engage at all [1].

The specific credential at the base of that foundation is different in each category, HIPAA documentation, FDA clearance pathways and CMS reimbursement rules in healthcare; MAS licensing, VARA and DIFC frameworks, and Visa BIN sponsorship terms in stablecoin infrastructure, but the rule that governs it is the same rule: nothing else in the go-to-market motion works until this layer is in place.

Both playbooks independently distrust the same channels

The channel guidance converges almost word for word. Healthcare’s playbook notes that “paid digital tends to underperform for enterprise health tech because the buying process is relationship-driven and committee-based,” and that the highest-performing channels are industry events, targeted outbound built on real research, and referral networks among health system leaders who rely on peer validation [1].

Fintech’s playbook reaches the same conclusion independently: product-led growth “does not work for enterprise fintech selling into regulated institutions,” paid search underperforms because “buyers do not make procurement decisions based on a Google search,” and the channels that actually produce pipeline are industry events, referral and partner networks, and targeted outbound [2]. Two playbooks, written for categories with no obvious connection to each other, arrive at the same channel mix through the same reasoning: a compliance officer does not self-serve a purchase decision, no matter how good the landing page is.

Compliance becomes a moat in both, once companies stop treating it as friction

Both playbooks make the same counterintuitive argument about compliance itself. Healthcare’s guidance calls for “reframing compliance: from obstacle to competitive advantage,” noting that a health system’s security team reviewing thorough, current documentation clears the biggest hurdle in the sales process, while a competitor with gaps is eliminated outright [1].

Fintech’s guidance makes the identical case in near-identical language: “compliance is not a constraint on your marketing, it is a competitive advantage when done well,” because a buyer who cannot rely on vague claims forces a vendor to be specific, and specificity reads as credibility [2]. Neither playbook treats compliance as a cost center. Both treat it as the asset a competitor cannot copy in a quarter, because it takes years to build and compounds once it exists.

Hiring from the industry shows up as best practice in both, independently

The clearest convergence is in hiring advice. Healthcare’s playbook argues that companies build clinical credibility fastest when “they hire from the industry,” not only in clinical roles but across the organization, because a marketing lead who spent years inside a health system writes differently than one from a standard SaaS background [1].

Fintech’s playbook makes the same recommendation almost word for word: “your GTM team should include people who have worked at financial institutions,” because a rep with a banking background can have a conversation a typical SaaS SDR cannot [2]. Neither source cites the other. Both arrived at the same conclusion because both are describing what happens when a buyer can detect inauthenticity instantly, which any sufficiently regulated, high-trust category seems to produce on its own.

Two companies, one playbook, run in two directions

None of this is a claim about how any specific company actually staffs or organizes itself; that’s internal information neither company has disclosed. But it is worth checking the pattern against what is publicly visible at two companies building in these two categories, Intellect in mental healthcare and StraitsX in stablecoin payment infrastructure, because both look like they are running the same underlying playbook rather than two unrelated ones.

Intellect’s public partnership history reads like the healthcare playbook’s compliance-moat and ecosystem-distribution principles applied directly. Its 2023 strategic partnership with IHH Healthcare, Asia’s largest private healthcare group, ran a pilot through Gleneagles Hospital Singapore before extending to IHH’s corporate clients and employees, the kind of hospital-network relationship that signals clinical integration in exactly the way the playbook describes [3][8].

Its partnership with Accresa and Ameriflex met the compliance and benefits-processing standards required to serve more than 55,000 US employer groups, and its multi-year Singapore government contract, which Intellect’s Cassandra Loh has said mattered less for its size than for “the confidence that the government has in us,” reads as the kind of institutional trust signal both playbooks treat as foundational [3]. Nothing in the public record confirms how Intellect’s commercial team is actually structured, but the moves are consistent with a company executing the regulated-trust sequence the healthcare literature describes.

StraitsX’s public job postings and product case studies describe the same sequence inside fintech. A Dubai-based Sales Manager role, scoped around GCC institutional clients and built explicitly around DIFC and VARA compliance rather than Singapore’s MAS regime, reads as regulatory-environment segmentation, the exact practice the fintech playbook recommends over targeting a category broadly [4]. Its recent case study crediting RedotPay’s top ranking in annual card volume to StraitsX’s underlying Visa BIN sponsorship and settlement infrastructure reads as compliance turned into product, not overhead [6]. And CEO Tianwei Liu’s own framing of trust, in the context of a whitepaper StraitsX co-published with the Singapore FinTech Association and Visa, “Blockchain gives us the rails, but trust is still built by the people and systems behind the scenes” [7], is close to a direct restatement of the trust hierarchy that both playbooks independently describe.

Neither company’s public footprint proves the underlying playbook is universal. But it is hard to look at a mental health platform’s hospital partnerships and a stablecoin infrastructure company’s regional compliance hub side by side and conclude they are following unrelated logics. They look, from the outside, like two very different businesses solving the same problem the same way, because the problem, selling something a regulator has to bless before anyone else can trust it, does not change much between industries.

References

1. Jamie Partridge, “Healthcare Technology Go-to-Market Strategy [2026],” UpliftGTM, 1 April 2026. https://upliftgtm.com/blog/healthcare-tech-go-to-market
2. Jamie Partridge, “Fintech Go-to-Market Strategy: The Complete Playbook [2026],” UpliftGTM, 1 April 2026. https://upliftgtm.com/blog/fintech-go-to-market-strategy
3. Paulo Joquino, “Building the Market, Not Just the Product: A Case Study on Intellect,” Insignia Business Review, 21 March 2025. https://review.insignia.vc/2025/03/21/intellect-case-study/
4. StraitsX, “Sales Manager” job posting, Greenhouse, accessed September 2026. https://job-boards.eu.greenhouse.io/straitsx/jobs/4920834101
5. StraitsX, “Crypto OTC Sales Manager” job posting, Built In, accessed September 2026. https://builtin.com/job/crypto-otc-sales-manager/10129746
6. StraitsX, LinkedIn company page, RedotPay card-infrastructure case study, 17 September 2026. https://www.straitsx.com (case study: https://lnkd.in/geyZx4TV)
7. “5 Things We’re Learning About Agentic Commerce From a New Industry Playbook with StraitsX,” Insignia Business Review, 10 September 2026. https://review.insignia.vc/2026/09/10/agentic-commerce-straitsx/
8. Catherine Shu, “Mental health startup Intellect partners with Asia’s largest private healthcare group,” TechCrunch, 14 March 2023. https://techcrunch.com/2023/03/14/intellect-ihh/